$2.63 Billion is the total value of Tekla Capital Management LLC's 177 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 37.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNH | Sell | Unitedhealth Group Inc. | $110,667,818 | -22.8% | 234,173 | -13.4% | 4.21% | -22.2% |
| AZN | Sell | AstraZeneca PLCsponsored adr | $68,900,808 | -0.6% | 992,664 | -2.9% | 2.62% | +0.2% |
| ABT | Sell | Abbott Laboratories | $63,171,557 | -17.0% | 623,855 | -10.0% | 2.40% | -16.3% |
| BMY | Sell | Bristol-Myers Squibb Company | $46,007,701 | -7.0% | 663,796 | -3.5% | 1.75% | -6.2% |
| IDXX | Sell | IDEXX Laboratories, Inc. | $29,302,188 | +5.5% | 58,595 | -13.9% | 1.12% | +6.4% |
| BSX | Sell | Boston Scientific Corp. | $28,316,480 | -19.2% | 565,990 | -25.2% | 1.08% | -18.5% |
| HCA | Sell | HCA Healthcare, Inc. | $23,389,207 | -7.2% | 88,703 | -15.5% | 0.89% | -6.5% |
| JAZZ | Sell | Jazz Pharmaceuticals plcshares | $21,624,501 | -25.7% | 147,779 | -19.2% | 0.82% | -25.2% |
| SYK | Sell | Stryker Corp. | $20,433,372 | -49.1% | 71,578 | -56.4% | 0.78% | -48.6% |
| HUM | Sell | Humana Inc. | $17,862,015 | -55.1% | 36,794 | -52.7% | 0.68% | -54.8% |
| NVO | Sell | Novo Nordisk A/Ssponsored adr | $17,715,942 | +0.3% | 111,323 | -14.7% | 0.67% | +1.0% |
| MOH | Sell | Molina Healthcare, Inc. | $16,545,861 | -31.9% | 61,856 | -16.0% | 0.63% | -31.4% |
| EW | Sell | Edwards Lifesciences Corp. | $14,158,909 | +10.7% | 171,146 | -0.1% | 0.54% | +11.6% |
| UTHR | Sell | United Therapeutics Corp. | $13,706,352 | -57.2% | 61,200 | -46.8% | 0.52% | -56.8% |
| LH | Sell | Laboratory Corporation of America Holdings | $9,186,436 | -11.6% | 40,042 | -9.3% | 0.35% | -10.9% |
| ZBH | Sell | Zimmer Biomet Holdings, Inc. | $8,702,395 | -73.6% | 67,356 | -74.0% | 0.33% | -73.5% |
| LNTH | Sell | Lantheus Holdings, Inc. | $6,563,107 | -62.4% | 79,495 | -76.8% | 0.25% | -62.1% |
| VECT | Sell | VectivBio Holding AG | $5,872,372 | -7.5% | 682,834 | -7.4% | 0.22% | -6.7% |
| BCRX | Sell | BioCryst Pharmaceuticals, Inc. | $4,207,764 | -45.5% | 504,528 | -25.0% | 0.16% | -45.2% |
| CTLT | Sell | Catalent, Inc. | $3,246,468 | -42.7% | 49,406 | -60.8% | 0.12% | -42.1% |
| ALGN | Sell | Align Technology, Inc. | $2,313,920 | -78.4% | 6,925 | -86.4% | 0.09% | -78.3% |
| MRUS | Sell | Merus N.V. | $1,270,060 | -11.1% | 69,025 | -25.2% | 0.05% | -11.1% |
| ZLAB | Sell | Zai Lab Ltd.adr | $1,152,126 | -13.3% | 34,640 | -20.0% | 0.04% | -12.0% |
| Sell | Theseus Pharmaceuticals, Inc. | $666,000 | +33.7% | 75,000 | -25.0% | 0.02% | +31.6% | |
| STRO | Sell | Sutro Biopharma, Inc. | $454,395 | -61.9% | 98,354 | -33.3% | 0.02% | -62.2% |
| VYNE | Exit | VYNE Therapeutics Inc. | $0 | – | -135,395 | -100.0% | -0.00% | – |
| FVE | Exit | AlerisLife Inc. | $0 | – | -24,237 | -100.0% | -0.00% | – |
| CRBP | Exit | Corbus Pharmaceuticals Holdings, Inc. | $0 | – | -154,310 | -100.0% | -0.00% | – |
| ONEM | Exit | 1Life Healthcare, Inc. | $0 | – | -31,266 | -100.0% | -0.02% | – |
| PLRX | Exit | Pliant Therapeutics, Inc. | $0 | – | -35,233 | -100.0% | -0.03% | – |
| ACAD | Exit | ACADIA Pharmaceuticals Inc. | $0 | – | -72,225 | -100.0% | -0.04% | – |
| MORF | Exit | Morphic Holding, Inc. | $0 | – | -44,625 | -100.0% | -0.04% | – |
| Exit | Stevanato Group Societa' Per Azioniordinary shares | $0 | – | -71,190 | -100.0% | -0.05% | – | |
| PTGX | Exit | Protagonist Therapeutics, Inc. | $0 | – | -122,271 | -100.0% | -0.05% | – |
| ARVN | Exit | Arvinas, Inc. | $0 | – | -42,998 | -100.0% | -0.06% | – |
| IDYA | Exit | IDEAYA Biosciences, Inc. | $0 | – | -133,185 | -100.0% | -0.09% | – |
| Exit | MoonLake Immunotherapeutics AG | $0 | – | -300,000 | -100.0% | -0.12% | – | |
| XNCR | Exit | Xencor, Inc. | $0 | – | -200,328 | -100.0% | -0.20% | – |
| HQY | Exit | HealthEquity, Inc. | $0 | – | -110,214 | -100.0% | -0.26% | – |
| HZNP | Exit | Horizon Therapeutics plc | $0 | – | -415,053 | -100.0% | -1.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.